Biotech company NasVax Ltd. (TASE: NSVX) said today that after the Helsinki (ethics) committee at Jerusalem's Hadassah Medical Center, as well as the Ministry of Health, previously approved a Phase IIa clinical trial to study one of its treatments for liver disease, the company has begun delivering the treatment to patients.
Nasvax will conduct the trial to study its oral anti-CD3 immunotherapy treatment against non-alcoholic steatohepatitis or fatty liver (NASH) in patients who also have diabetes.
Oral anti-CD3 immunotherapy treatment is based on a licensed monoclonal antibody (MAb) which is used in preventing transplant rejection when given by injection. The company hopes the oral version can treat certain inflammatory and autoimmune diseases, including immune-mediated hepatitis, NASH, type-2 diabetes, type-I diabetes, lupus, colitis, arthritis, and others.
Published by Globes [online], Israel business news - www.globes-online.com - on September 12, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010